CVB Financial Stock Hits New 52-Week High (CVBF)

NEW YORK ( TheStreet) -- CVB Financial Corporation (Nasdaq: CVBF) hit a new 52-week high Friday as it is currently trading at $11.23, above its previous 52-week high of $11.22 with 84,188 shares traded as of 10:20 a.m. ET. Average volume has been 779,600 shares over the past 30 days.

CVB Financial has a market cap of $1.14 billion and is part of the financial sector and banking industry. Shares are up 8.4% year to date as of the close of trading on Thursday.

CVB Financial Corp. operates as a bank holding company for Citizens Business Bank that provides various banking and trust services for small and medium-sized businesses, professionals, and individuals. The company has a P/E ratio of 14.1, equal to the average banking industry P/E ratio and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates CVB Financial as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, expanding profit margins, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full CVB Financial Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus